OS Therapies - 预计在2025年1月提交Ost-Her2的美国生物制品许可申请和英国MHRA市场授权申请
OS Therapies - 预计在2025年1月提交Ost-Her2的美国生物制品许可申请和英国MHRA市场授权申请
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.